Adagene (ADAG) Competitors $2.05 +0.04 (+1.99%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ADAG vs. DSGN, BTMD, NGNE, VYGR, PROC, CTNM, SLRN, TNGX, KMDA, and CGCShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Design Therapeutics (DSGN), biote (BTMD), Neurogene (NGNE), Voyager Therapeutics (VYGR), Procaps Group (PROC), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Tango Therapeutics (TNGX), Kamada (KMDA), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Adagene vs. Design Therapeutics biote Neurogene Voyager Therapeutics Procaps Group Contineum Therapeutics Acelyrin Tango Therapeutics Kamada Canopy Growth Adagene (NASDAQ:ADAG) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership. Does the MarketBeat Community believe in ADAG or DSGN? Adagene received 11 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 80.77% of users gave Adagene an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformAdageneOutperform Votes2180.77% Underperform Votes519.23%Design TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Is ADAG or DSGN more profitable? Adagene's return on equity of 0.00% beat Design Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Design Therapeutics N/A -18.01%-17.38% Do institutionals & insiders believe in ADAG or DSGN? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 31.2% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media favor ADAG or DSGN? In the previous week, Design Therapeutics had 4 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Design Therapeutics and 0 mentions for Adagene. Design Therapeutics' average media sentiment score of 0.86 beat Adagene's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adagene Neutral Design Therapeutics Positive Which has more volatility and risk, ADAG or DSGN? Adagene has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Which has preferable valuation & earnings, ADAG or DSGN? Adagene has higher revenue and earnings than Design Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$815.75K111.25-$18.95MN/AN/ADesign TherapeuticsN/AN/A-$66.86M-$0.85-7.35 Do analysts rate ADAG or DSGN? Adagene currently has a consensus target price of $5.00, suggesting a potential upside of 143.90%. Design Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 12.00%. Given Adagene's stronger consensus rating and higher probable upside, analysts plainly believe Adagene is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryAdagene beats Design Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdagenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.76M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales111.25195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book1.275.104.794.78Net Income-$18.95M$151.51M$120.07M$225.60M7 Day Performance-0.49%-2.15%-1.90%-1.23%1 Month Performance-9.29%-3.14%11.45%3.37%1 Year Performance18.50%11.50%30.63%16.58% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.0012 of 5 stars$2.05+2.0%$5.00+143.9%+13.9%$90.76M$815,746.000.00260DSGNDesign Therapeutics0.926 of 5 stars$6.37+13.8%$7.00+9.9%+143.2%$360.68MN/A-7.1840News CoveragePositive NewsBTMDbiote3.2421 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpNGNENeurogene3.7244 of 5 stars$23.87+1.5%$60.83+154.9%N/A$354.59M$925,000.000.0090VYGRVoyager Therapeutics4.6047 of 5 stars$6.48+3.3%$17.00+162.3%-27.6%$354.00M$250.01M8.83100PROCProcaps Group0.9123 of 5 stars$3.09+28.2%N/A-20.3%$348.61M$414.10M5.105,500News CoverageGap UpCTNMContineum Therapeutics1.9464 of 5 stars$13.52-3.6%$29.25+116.3%N/A$348.55M$50M0.0031News CoverageSLRNAcelyrin2.5887 of 5 stars$3.44+6.5%$11.75+241.6%-55.8%$345.14MN/A-1.31135TNGXTango Therapeutics1.8423 of 5 stars$3.18+3.9%$13.14+313.3%-68.5%$341.59M$43.38M-2.5990News CoverageKMDAKamada3.8898 of 5 stars$5.84-0.5%$14.50+148.3%-1.2%$335.68M$158.38M20.96360Positive NewsCGCCanopy Growth2.4388 of 5 stars$3.07-1.3%$3.50+14.0%-41.0%$334.45M$220.27M-0.631,029Analyst RevisionNews Coverage Related Companies and Tools Related Companies DSGN Competitors BTMD Competitors NGNE Competitors VYGR Competitors PROC Competitors CTNM Competitors SLRN Competitors TNGX Competitors KMDA Competitors CGC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADAG) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
